The apolipoprotein E (APOE) gene is the strongest genetic risk factor for late-onset Alzheimer disease. Previous studies suggest that reduction of apoE levels through genetic manipulation can reduce Aβ pathology. However, it is not clear how reduction of apoE levels after birth would affect amyloid deposition. We utilize an antisense oligonucleotide (ASO) to reduce apoE expression in the brains of APP/PS1-21 mice homozygous for the APOE-ε4 or APOE-ε3 allele. ASO treatment starting after birth led to a significant decrease in Aβ pathology when assessed at 4 months. Interestingly, ASO treatment starting at the onset of amyloid deposition led to an increase in Aβ plaque size and a reduction in plaque-associated neuritic dystrophy with no change in overall plaque load. These results suggest that lowering apoE levels prior to plaque deposition can strongly affect the initiation of Aβ pathology while lowering apoE after Aβ seeding modulates plaque size and toxicity.
Pubmed ID: 29216448 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
A commercial graphing software company that offers scientific software for statistical analyses, curve fitting and data analysis. It offers four programs: Prism, InStat, StatMate and QuickCalcs.
View all literature mentionsImaris provides range of capabilities for working with three dimensional images. Uses flexible editing and processing functions, such as interactive surface rendering and object slicing capabilities. And output to standard TIFF, Quicktime and AVI formats. Imaris accepts virtually all image formats that are used in confocal microscopy and many of those used in wide-field image acquisition.
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis unknown targets Goat IgG (H+L)
View all literature mentionsThis unknown targets Biotin
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis monoclonal targets beta-Amyloid 1-16
View all literature mentionsThis polyclonal targets Actin
View all literature mentionsThis polyclonal targets IgG (H+L)
View all literature mentionsThis polyclonal targets IgG (H + L)
View all literature mentionsThis polyclonal targets beta Tubulin (H-235)
View all literature mentionsThis polyclonal targets donkey anti-mouse IgG-HRP
View all literature mentionsThis monoclonal targets GFAP
View all literature mentionsThis polyclonal targets Rat IgG
View all literature mentionsThis monoclonal targets Mouse CD45
View all literature mentionsThis monoclonal targets Amyloid β (N)
View all literature mentionsMus musculus with name B6.129P2-Apoetm2(APOE*3)Mae N8 from IMSR.
View all literature mentionsMus musculus with name B6.129P2-Apoetm3(APOE*4)Mae N8 from IMSR.
View all literature mentions